Here's a teaser of the sportscar that could become Mercedes' next GT3 model
What the German manufacturer is calling the Concept AMG GT Track Sport is described as an 'uncompromising concept vehicle' that has been 'designed for absolute driving dynamic peak performance to set new standards and record times'.
It demonstrates Mercedes-AMG's 'great expertise as a sportscar manufacturer and provides a preview of a possible expansion of the GT series', the short statement accompanying camouflaged images of the concept car continued.
No mention was made of racing or the GT3 category, but the statement revealed that the car 'offers an exclusive insight into the development workshop in Affalterbach'.
That is a reference to the new Affalterbach Racing GmbH division established last year on the takeover of the HWA organisation that developed the previous two Mercedes GT3 contenders, the SLS and AMG respectively released to customers in 2011 and 2016.
Mercedes announced the start of the new company last July at the same time as revealing that a successor to the AMG GT3 would be developed at its facilities to the north of Stuttgart.
Mercedes AMG Concept AMG GT Track Sport
The only technical detail of the concept car acknowledged by Mercedes is that it is powered by a V8 engine like the first two GT3 racers.
The 6.2-litre normally-aspirated powerplant was carried over from the SLS to the AMG GT3 even though there was no such engine in the road car range of the latter machine.
Mercedes appears to be developing what might be described as a racer for the road in order to remain in a category in which it has enjoyed considerable success, including a pair of victories in each of the 24-hour classics at Spa and the Nurburgring.
A study of the C192 model GT, introduced in 2023 to replace the C190 on which the current Mercedes-AMG GT3 is based, determined the car's unsuitability for motorsport.
It is a 2+2 rather than a two-seater like its predecessor.
No timeline was mentioned in the Mercedes statement for a possible introduction of the car, though it suggested that a commencement of testing is imminent.
It talked of the project being 'finalised' prior to the concept car 'proving itself on the test tracks'.
Read Also:
George Russell 'at peace' with future as Mercedes focus on results after Max Verstappen talks
To read more Motorsport.com articles visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Motor 1
10 minutes ago
- Motor 1
Mission Accomplished: The Corvette ZR1X Broke Ford's Nürburgring Record
Chevrolet has tested Corvettes around the Nürburgring for decades, but it's been over 10 years since the company released a Nordschleife lap time for America's sports car. That changes Thursday. Chevy brought three C8 Corvettes to the 'Ring—the Z06, ZR1, and ZR1X —and now claims the title of fastest American car around the German circuit. Both the ZR1 and ZR1X beat the Ford Mustang GTD's 6:52.072 . The ZR1 managed a 6:50.763 while the hybrid ZR1X shaved that time down to 6:49.275, even beating out the Porsche 911 GT3 RS. Meanwhile, the Z06 set a very respectable 7:11.826. Corvette ZR1X — 6:49.275 Corvette ZR1 — 6:50.763 Corvette Z06 — 7:11.826 All three Corvettes were stock production cars except for some safety modifications—a roll hoop, a bucket seat, a six-point harness, and a fire-suppression system. Each featured its respective optional performance package and Michelin Pilot Sport Cup 2 R tires. The Nürburgring officially considers these prototype cars, however, as the Z06 was a US-spec model, and the ZR1 and ZR1X aren't sold in Europe. Photo by: Chevrolet Photo by: Chevrolet The lap times were set by Corvette engineers, not professional race-car drivers, a fact that Chevy is proud of. Vehicle performance manager Aaron Link set the time in the Z06, vehicle dynamics engineer Brian Wallace set the time in the ZR1, and fellow vehicle dynamics engineer Drew Cattell set the time in the ZR1X. GM Motorsport boss Ken Morris noted in a statement: 'We've created a different kind of relationship between our cars, iconic tracks, and our engineers, it is how we develop our vehicles. These Corvettes weren't piloted by pro race-car drivers. They were driven by the same engineers who designed, engineered, and tuned them. Brian, Aaron and Drew have grown into world-class drivers and even better engineers. Their lap times now rank among the fastest ever recorded by non-professionals at the Ring, which is so cool.' By contrast, sports-car ace Dirk Müller set the Mustang GTD's Nurburgring time, while longtime Porsche factory driver Jörg Bergmeister did the job for the 911 GT3 RS. Mercedes-AMG factory driver Maro Engel is the only one to have pedaled stock production cars around the Nürburging quicker than the Cattell in the ZR1X, with his laps in the AMG GT Black Series and One hypercar. Chevy put out a documentary on the Nürburgring project, and it features a lot of good insight into the process. Setting a fast lap at the 'Ring required a lot of simulation and development work back in Michigan, a fair share of logistical challenges, and fate, in the form of dry conditions. Plus lots and lots of Michelins. The Corvette ZR1 already has production-car lap records around Road America, Road Atlanta, Watkins Glen, and both full and grand course configurations of Virginia International Raceway. One imagines Corvette engineers wanting to go better with the 1,250-horsepower ZR1X, and rivals wanting to take the Vette down. More on the Corvette Why An Electric Corvette Won't Happen Anytime Soon 'Not the End of the Story:' An Even Crazier Corvette ZR1X Could Still Happen Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Yahoo
38 minutes ago
- Yahoo
EU commercial vehicle registrations decline in H1 2025: ACEA report
The European Automobile Manufacturers' Association (ACEA) has revealed a 13.2% drop in new EU van registrations, with the three largest markets contributing to the decline. Germany's market experienced the largest drop, with a 14.7% reduction in registrations. France and Italy also saw notable declines of 12% and 11.7%, respectively. In contrast, Spain recorded an 11.2% rise in new van registrations. The truck segment did not fare any better, with a 15.4% decrease in new EU truck registrations, amounting to 155,367 units. The heavy-truck segment was particularly affected, with a 14.5% fall in registrations, while the medium-truck segment saw a 20% decline. All major markets, including Germany, France, Spain, and Italy, faced double-digit percentage drops. The bus segment also reported a reduced demand compared to the first half of the previous year, with a total of 18,123 units registered. Despite the overall reduction in vehicle registrations, there are changes in fuel type preferences among buyers. Diesel-powered vans still lead the market but have seen a decrease in market share from 84.3% to 82%, with a 15.6% fall in registrations. Petrol-powered vans now hold a 4.9% share after a 29.8% decline. Electrically chargeable vans have increased their market share to 9.5%, up from 5.8% in the previous year. Hybrid vans, although growing by 7.1%, remain a smaller portion of the market with a 2.6% share. The truck market continues to be dominated by diesel, with a 93.6% share despite a 15.4% drop in registrations. Electrically chargeable trucks have made gains, now holding a 3.6% market share, with the Netherlands showing a significant 187.6% increase in registrations in this category. In the bus sector, the share of electrically chargeable bus registrations has risen from 16.4% to 21.6%. Hybrid-electric buses have declined by 35.5%, and diesel buses, while still predominant, have decreased to a 64.7% market share. In a statement, the ACEA said: 'The first half of 2025 proved challenging for the EU's commercial vehicle market, marked by significant registration declines in key markets, amidst an already challenging economic context. 'While the electrically chargeable share increased, the growth trajectory is still not fast enough as market uptake continues to be stymied by the near absence of essential enabling conditions.' A recent ACEA report also revealed a drop of 1.9% in the EU's new car registrations for H1 2025, compared to the same period last year. "EU commercial vehicle registrations decline in H1 2025: ACEA report" was originally created and published by Motor Finance Online, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Immunophotonics Completes Treatment of Last Patient in INJECTABL-1 Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors
IP-001, Immunophotonics' proprietary glycan polymer, is designed to transform tumor ablation into personalized systemic cancer immunotherapies ST. LOUIS, July 31, 2025 /PRNewswire/ -- Immunophotonics, Inc., a clinical-stage biotech company developing novel immunostimulatory drugs to improve efficacy of routine tumor destruction techniques, has announced the completion of treatment of the last patient in its INJECTABL-1 multicenter Phase 1b/2a clinical trial of IP-001 for advanced solid tumors. The 41-patient trial, which focused on three distinct cancer types — colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma— was conducted in France, Germany, Switzerland, the UK, and the US. The INJECTABL-1 trial was designed to evaluate the systemic immune-mediated anti-cancer effects of IP-001 following tumor ablation, which aims to destroy all cells in targeted tumor lesions in patients with advanced solid tumors but fails to induce robust anti-tumor immunity. Tumor ablation is an approved and well-established procedure that is readily available at most hospitals and clinics. IP-001 is a novel immunotherapy administered by injection into the ablation zone. It works by retaining tumor debris, including tumor antigens, and by activating the patient's own immune system to allow systemic tumor surveillance. Such immune surveillance enables the patient's own defense mechanisms to recognize and destroy tumor cells that had escaped the destroyed metastatic lesion. Prof. Dr. Markus Jörger, Principal Investigator for the trial at the Cantonal Hospital St. Gallen Clinic for Medical Oncology and Hematology, commented: "We are proud to announce the completion of treatment of the last patient in our INJECTABL-1 Phase 1b/2a clinical trial. This significant milestone brings us closer to potentially providing a new treatment option for patients with advanced solid tumors." "Immunophotonics is committed to leading the field of Interventional Immuno-Oncology® through a therapeutic approach intended to reduce tumor recurrence after standard-of-care local ablation therapy, which remains a significant unmet medical need. With the completion of our INJECTABL-1 trial, we will evaluate data to assess IP-001's ability to transform ablation into something more powerful as we continue to advance the clinical development of our proprietary novel asset. Early signals are positive, and the company has expanded clinical collaborations to further assess the efficacy of this novel therapy," stated Lu Alleruzzo, Immunophotonics co-founder and CEO. About IP-001IP-001 is a proprietary glycan polymer that generates tumor antigen depots and acts as a potent, multimodal immune stimulant intended to induce immunological responses to eradicate cancer. IP-001 is designed to (1) prolong the availability of the targeted tumor antigens, (2) facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) lead to a downstream adaptive immune response against the tumor cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumor cells throughout the body. About ImmunophotonicsImmunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology®. IP-001, which is the first asset from the company's intellectual property platform and is currently assessed in multiple clinical trials, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific immune response in solid cancers. By combining routine energy therapies, such as ablation or radiation, with injection of its proprietary immunoadjuvant (IP-001), Immunophotonics aims to trigger a systemically active anti-cancer immune response that can destroy circulating tumor cells and micrometastases left behind after ablation. The company's world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland. For more information, visit Cautionary Note Regarding Forward-Looking StatementsThis press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law. Investor Contacts:Tiberend Strategic Advisors, Nugentjnugent@ orDavid Irishdirish@ View original content to download multimedia: SOURCE Immunophotonics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
